Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Scopolamine to Augment ECT in Depression
NCT01312844Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2010
- Primary completion
- Jul 2012
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of scopolamine in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Started Apr 2010; status: terminated.
02
Drugs
scopolamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01312844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01312844.